Zevra Therapeutics, Inc. (ZVRA): Cash & Equivalents
$62.41M
As of 2025-12-31
$145.32M
As of 2026-06-30
-1.6%
3-year compound annual growth
+71.4%
5-year compound annual growth
+6.8%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.41M | +84.7% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $33.78M | -21.5% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $43.05M | -34.2% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $65.47M | -41.7% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $112.35M | n/m | 2023-03-07, Balance as of period end |
| 2020-12-31 | $4.21M | +31.0% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $3.22M | -82.5% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $18.41M | +69.3% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $10.87M | -35.1% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $16.76M | -48.1% | 2018-03-30, Balance as of period end |
| 2015-12-31 | $32.32M | +215.1% | 2017-03-10, Balance as of period end |
| 2014-12-31 | $10.26M | +420.8% | 2017-03-10, Balance as of period end |
| 2013-12-31 | $1.97M | n/a | 2016-03-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $62.41M | +84.7% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $41.16M | -37.7% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $110.75M | -35.6% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $37.07M | +213.8% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $154.97M | -0.3% |
| Xencor Inc (XNCR) | 2025-12-31 | $54.07M | +32.3% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $122.52M | +29.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.27M | -2.3% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
Compare ZVRA, ZYME, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗